Clinical Trials Logo

Brain Metastasis clinical trials

View clinical trials related to Brain Metastasis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06462079 Not yet recruiting - Brain Metastasis Clinical Trials

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Start date: June 15, 2024
Phase: Phase 2
Study type: Interventional

The incidence of brain metastasis of Her2-negative breast cancer is high, which seriously affects the prognosis of patients.The treatment of brain metastasis of Her2-negative breast cancer is still tricky. The local efficacy of head radiotherapy for breast cancer brain metastases is remarkable, and systemic tumor progression in patients with brain metastases is the main reason for treatment failure. Sacituzumab Govitecan is the only Trop-2 antibody-coupled drug (ADC) approved for the treatment of unresectable locally advanced or metastatic Her2-negative breast cancer. However, the objective remission rate of Sacituzumab Govitecan for intracranial metastatic lesions has not been satisfactory. This study is an open, uncontrolled phase II clinical study to observe the efficacy and safety of Sacituzumab Govitecan combined with intracranial radiotherapy in the treatment of patients with brain metastases from Her2-negative breast cancer, in order to find a more effective treatment method.

NCT ID: NCT06210438 Not yet recruiting - Brain Metastasis Clinical Trials

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This is a phaseâ…¡, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases

NCT ID: NCT02832635 Not yet recruiting - Brain Metastasis Clinical Trials

A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases

Start date: July 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effects on neurocognitive function of whole-brain radiotherapy (WBRT) with/without TMZ concurrent chemotherapy or avoidance of hippocampus for patients of brain metastases, as well as the feasibility and risk of avoidance of hippocampus during whole-brain radiotherapy.

NCT ID: NCT02448576 Not yet recruiting - Breast Cancer Clinical Trials

PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy

Start date: August 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to compare whether prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy could prolong brain-metastasis free survival.